Compare RMBI & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMBI | FATE |
|---|---|---|
| Founded | 1887 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.0M | 125.6M |
| IPO Year | 2019 | 2013 |
| Metric | RMBI | FATE |
|---|---|---|
| Price | $15.16 | $2.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 50.5K | ★ 4.5M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | 27.17 | ★ 29.88 |
| EPS | ★ 0.28 | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $54.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.77 | $0.91 |
| 52 Week High | $16.59 | $3.21 |
| Indicator | RMBI | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 51.72 | 67.37 |
| Support Level | $13.10 | $1.01 |
| Resistance Level | $16.04 | N/A |
| Average True Range (ATR) | 0.56 | 0.28 |
| MACD | 0.06 | 0.10 |
| Stochastic Oscillator | 33.49 | 79.34 |
Richmond Mutual Bancorp Inc is a bank holding company. Along with its subsidiary, it is mainly engaged in attracting deposits from the general public, as well as brokered deposits, and investing those funds in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one- to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. It also obtains funds by utilizing Federal Home Loan Bank (FHLB) advances. These funds are generally invested in investment securities, including mortgage-backed and mortgage-related securities and agency and municipal bonds. The Group's primary market area includes Wayne and Shelby counties in Indiana and Shelby, Miami, and Franklin counties in Ohio.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.